



# Correction to: How Does the Public Evaluate Vaccines for Low-Incidence, Severe-Outcome Diseases? A General-Population Choice Experiment

F. Reed Johnson<sup>1</sup> · Angelyn Fairchild<sup>2</sup> · Dale Whittington<sup>3,4</sup> · Amit K. Srivastava<sup>5,8</sup> · Juan Marcos Gonzalez<sup>6</sup> · Liping Huang<sup>7</sup>

Published online: 13 March 2023

© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023

## Correction to:

**The Patient - Patient-Centered Outcomes Research  
(2023) 16:139–151**

<https://doi.org/10.1007/s40271-022-00602-x>

In this article the author name Liping Huang was incorrectly written as Liping Huan.

The original article has been corrected.

---

The original article can be found online at <https://doi.org/10.1007/s40271-022-00602-x>.

---

✉ F. Reed Johnson  
reed.johnson@duke.edu

<sup>1</sup> Duke Clinical Research Institute, Duke University, 300 West Morgan Street, Durham, NC 27701, USA

<sup>2</sup> Angelyn Fairchild Kenan-Flagler School of Business, University of North Carolina, Chapel Hill, NC, USA

<sup>3</sup> Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA

<sup>4</sup> Global Development Institute, University of Manchester, Manchester, UK

<sup>5</sup> Medical Development and Scientific Clinical Affairs, Pfizer Vaccines, Collegeville, PA, USA

<sup>6</sup> Duke Clinical Research Institute, Duke University, Durham, NC, USA

<sup>7</sup> Health Economics and Outcomes Research, Pfizer Inc., Collegeville, PA, USA

<sup>8</sup> Orbital Therapeutics, Cambridge, MA, USA